Drug intelligence / Profile preview

111In-CHX-A''-DTPA trastuzumab

Development stage: Phase 1
Lead developer: National Cancer Institute
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**111In-CHX-A''-DTPA trastuzumab** is an investigational HER2-targeted radioimmunoconjugate developed by the National Cancer Institute for diagnostic imaging. It consists of the anti-HER2 humanized monoclonal antibody trastuzumab linked through the bifunctional chelator CHX-A''-DTPA to the gamma-emitting radionuclide indium-111. After intravenous administration at tracer doses, it binds human epidermal growth factor receptor 2-expressing tumor cells and enables whole-body gamma-camera or SPECT imaging of HER2 expression, lesion distribution, and tracer biodistribution. It is an imaging agent rather than a therapeutic radioimmunotherapy product.

Other names: 111Indium CHX-A DTPA trastuzumab111In-CHX-A''-DTPA-trastuzumabIndium-Herceptin

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on 111In-CHX-A''-DTPA trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 111In-CHX-A''-DTPA trastuzumab.

Explore the full profile